Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial

Summary Background Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin‐23 and interleukin‐17A, respectively, and are effective in adult patients with moderate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2021-01, Vol.184 (1), p.50-59
Hauptverfasser:	Warren, R.B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., Paul, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Clinical Trial Cytokines Dermatology Double-Blind Method Humans Life Sciences & Biomedicine Monoclonal antibodies Original Patients Psoriasis Psoriasis - drug therapy Quality of Life Safety Science & Technology Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!